



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Dony, et al.

Serial No

To Be Assigned

Filing Date

Herewith

For

USE OF A MELANOMA INHIBITING ACTIVITY FACTOR (MIA) FOR CARTILAGE AND BONE

REPAIR

April 2, 2001

Hon. Commissioner of Patents and Trademarks Washington. D.C. 20231

PRELIMINARY AMENDMENT

SIR

In advance of prosecution, please amend the above-identified patent application as follows:

IN THE CLAIMS:

Cancel claims 1-17, without prejudice.

Add the following new claims:

- A pharmaceutical composition comprising a melanoma inhibiting activity factor and at least one biocompatible and or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides and collagen.
- 19. A pharmaceutical composition comprising a melanoma inhibiting activity factor (MIA) in combination with an osteoinductive protein.
- 20 A pharmaceutical composition as claimed in claim 19, wherein the ratio of osteoinducive protein 1 MIA is 1 1 to 1 1 20.
- A pharmaceutical composition as claimed in claim 19, wherein said osteoinductive protein is selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein.